WCLC 2025 - Posters & ePosters-P3.18.10 Efficacy and Safety of Aumolertinib as Adjuvant Therapy in Resectable Stage IA3 EGFRm NSCLC With High Risk Factors

P3.18.10 Efficacy and Safety of Aumolertinib as Adjuvant Therapy in Resectable Stage IA3 EGFRm NSCLC With High Risk Factors

Back to course

Pdf Summary

This prospective, single-arm Phase II trial conducted in China evaluated the efficacy and safety of aumolertinib as adjuvant therapy in patients with resectable stage IA3 (T1cN0M0) EGFR-mutated non-small cell lung cancer (NSCLC) exhibiting high-risk factors. Thirty patients with pathologically confirmed NSCLC harboring EGFR exon 19 deletion or L858R mutations and presenting high-risk features such as spread through air spaces (STAS) and/or vascular invasion (VI) who underwent complete tumor resection (R0) were enrolled. Eligible patients were aged 18 or older with an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1. Participants received oral aumolertinib at 110 mg once daily for up to three years unless disease recurrence or unacceptable toxicity occurred. The study’s primary objective was to assess the therapeutic benefit and safety profile of aumolertinib as an adjuvant treatment in this specific population. This work builds on emerging evidence supporting targeted EGFR inhibition in early-stage NSCLC with high-risk pathological factors. The authors acknowledged the participation of all patients and their families in the trial. References cited include relevant clinical and translational studies on EGFR-mutant NSCLC treatments. Overall, the trial explores the potential of prolonged aumolertinib therapy to reduce recurrence risk and improve outcomes in resectable stage IA3 EGFR-mutant NSCLC patients, addressing an unmet need for optimized adjuvant strategies in this subgroup.

Asset Subtitle

Baiqin Zhao

Meta Tag

Speaker Baiqin Zhao

Topic Clinical Trials in Progress

Keywords

aumolertinib

adjuvant therapy

EGFR-mutated NSCLC

stage IA3 lung cancer

high-risk factors

spread through air spaces (STAS)

vascular invasion (VI)

EGFR exon 19 deletion

L858R mutation

phase II trial